ETFs

L&G Healthcare Breakthrough UCITS ETF

DOCG:LSE:GBX

L&G Healthcare Breakthrough UCITS ETF

  • Price (GBX)907.55
  • Today's Change-4.25 / -0.47%
  • Shares traded18.01k
  • 1 Year change19.35%
Data delayed at least 20 minutes, as of Oct 31 2024 15:04 BST.
More ▼

Asset allocation

Distribution

Type% Net assets% Short% Long
Non-UK stock97.72%0.00%97.72%
Cash1.19%0.22%1.41%
UK stock1.09%0.00%1.09%
UK bond0.00%0.00%0.00%
Non-UK bond0.00%0.00%0.00%
Other0.00%0.00%0.00%
As of Oct 24 2024
Weightings
Sectors
Sector% Net assetsCategory average
Healthcare97.34%92.03%
Technology1.48%0.31%
Financial Services0.00%1.06%
Consumer Cyclical0.00%0.65%
Industrials0.00%0.35%
Real Estate0.00%0.10%
Communication Services0.00%0.06%
Utilities0.00%0.01%
As of Oct 24 2024. Sectors weighting is calculated using only long position holdings of the portfolio.

Top 10 holdings

Top 10 holdings as a per cent of portfolio
--17.82%0.00%17.82%
Category average% Net assets% Short% Long
Company1 year changePortfolio weightLong allocation
Illumina Inc+35.55%1.90%
Intuitive Surgical Inc+92.14%1.89%
Natera Inc+206.46%1.84%
Axogen Inc+272.34%1.78%
Boston Scientific Corp+64.13%1.77%
Vertex Pharmaceuticals Inc+31.45%1.76%
Stryker Corp+31.85%1.75%
Koninklijke Philips NV+39.37%1.73%
Penumbra Inc+19.73%1.70%
Charles River Laboratories International Inc+6.07%1.70%
Per cent of portfolio in top 10 holdings: 17.82%
The performance data shown in tables and graphs on this page is calculated in GBP of the fund/index/average (as applicable), on a Bid To Bid / Nav to Nav basis, with gross dividends re-invested on ex-dividend date. Past performance is not necessarily a guide to future performance; unit prices may fall as well as rise.
The videos and white papers displayed on this page have not been devised by The Financial Times Limited ("FT"). FT has not selected, modified or otherwise exercised control over the content of the videos or white papers prior to their transmission, or their receipt by you. The videos, white papers and other documents displayed on this page are paid promotional materials provided by the fund company. Any prospectus you view on this page has not been approved by FT and FT is not responsible for the content of the prospectus.
The information made available to you does not constitute the giving of investment advice or an offer to sell or the solicitation of an offer to buy any security of any enterprise in any jurisdiction. The securities listed above are not registered and will not be registered for sale in the United Sates and cannot be purchased by U.S. investors as the securities can only be purchased in jurisdictions where they have been registered for sale or where an exemption from registration applies. The offer, sale or delivery of the securities within the United States or to, or for the account or benefit of, U.S. Persons is not permitted except pursuant to an exemption from registration under U.S. securities laws, which may not be available; and the availability of the information through the website does not alter or change the persons eligible to purchase the security.
All managed funds data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
All data shown on this page, unless noted otherwise is Data Source and Copyright: Morningstar, Inc. 2024
All Rights reserved
© 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.
Pricing for ETFs is the latest price and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.